tiprankstipranks
Trending News
More News >

Immutep Ltd Highlights Immune System Innovations at Healthcare Conference

Story Highlights
  • Immutep Ltd focuses on immune system solutions for cancer and autoimmune diseases.
  • The company presented its business update at a major healthcare conference, impacting its industry stance.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Immutep Ltd Highlights Immune System Innovations at Healthcare Conference

Confident Investing Starts Here:

Immutep Ltd ( (AU:IMM) ) has provided an update.

Immutep Ltd presented an update at the Jefferies Global Healthcare Conference in June 2025, highlighting its ongoing business activities. The presentation emphasized the company’s commitment to leveraging immune system capabilities to address cancer and autoimmune disorders, which could enhance its market position and influence stakeholders in the biotechnology industry.

The most recent analyst rating on (AU:IMM) stock is a Buy with a A$0.92 price target. To see the full list of analyst forecasts on Immutep Ltd stock, see the AU:IMM Stock Forecast page.

More about Immutep Ltd

Immutep Ltd is a biotechnology company focused on harnessing the power of the immune system to combat cancer and autoimmune diseases. The company operates in the healthcare sector and is listed on both the Australian Securities Exchange (ASX: IMM) and NASDAQ (IMMP).

YTD Price Performance: -21.92%

Average Trading Volume: 4,236,447

Technical Sentiment Signal: Strong Sell

Current Market Cap: A$416.2M

See more data about IMM stock on TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App